Tru-D to Attend and Exhibit at 2017 IDWeek
The first and only UV disinfection robot validated by a CDC-funded randomized clinical trial, Tru-D SmartUVC will attend and exhibit at IDWeek, October 4-8, 2017 in San Diego, California. Tru-D invites IDWeek attendees to its booth #647 to learn how its technology provides thorough room disinfection, reduces the risk of hospital-acquired infections (HAIs) and makes health care facilities cleaner and safer for patients and staff.
IDWeek is the combined annual meeting of the IDSA, SHEA, HIVMA and PIDS, where infectious disease professionals are able to meet, share experiences and collaborate for the improvement of patient care and public health. Geared toward health care professionals in infectious diseases and health care epidemiology and prevention, the conference is critical for those who want to stay current in the latest trends and technologies for excellence in patient care.
“Tru-D’s technology has been validated by more than a dozen third-party studies to show that it is capable of providing thorough room disinfection from one position in the room,” said Chuck Dunn, CEO and President of Tru-D SmartUVC. “The pioneer of the UV disinfection space, Tru-D continues to drive innovation and acceptance of UV disinfection technology to help keep health care environments safer for the next patient who enters a room.”
An automated, no-touch disinfection robot, Tru-D is brought in to a room after the environmental services (ES) staff cleans using traditional methods. Tru-D then operates from one position in the room and administers one cycle of UVC light, destroying up to 99.9 percent of harmful pathogens that can remain behind such as C. diff, MRSA, MERS, VRE, Ebola and many more. Once the cycle is finished, Tru-D alerts the operator via audio and/or text message that disinfection is complete, and Tru-D can be moved to the next room. Tru-D also delivers disinfection data to a secure myTru-D portal, allowing for real time documentation of the disinfection process, putting critical data directly in the hands of operators and administrators.
Tru-D was the only device of its kind selected for the first randomized clinical trial on UVC disinfection because of its Sensor360 technology that precisely measures the proper UV dose needed for every room, eliminating any chance for human error in the disinfection process. Results of the CDC-funded Benefits of Enhanced Terminal Room Disinfection (BETR-D) study proved that enhanced disinfection strategies that utilized Tru-D reduced the risk of acquisition and infection of four major superbugs by a cumulative 30 percent among patients who entered the same room.
Tru-D invites attendees to its booth #647 to learn more about how it reduces the risk of infections and improves patient outcomes.